QUANTUM LEAP HEALTHCARE COLLABORATIVE

Dcis - the re-evaluating conditions for active surveillance suitability as treatment: ductal carcinoma in situ (recast dcis) platform trial is a landmark phase 2 trial that is changing the lens through which we treat dcis. The study is aimed at preventing the progression of dcis to breast cancer and is evaluating three investigational endocrine therapy arms.with the objective to avoid over-treatment of low-risk dcis patients, this new trial offers dcis patients endocrine therapy with the intent to identify patients who are responsive to non-invasive treatment and have the option to omit surgery and be monitored via long-term active surveillance. (continued on schedule o)a key element in reducing over treatment of dcis is identifying biomarkers that reflect the risk of progression so that those with low-risk lesions are spared surgery. Recast dcis features the assessment of mri imaging and molecular-based biomarker analyses in addition to evaluating new investigational agents in this setting. If patients and their physicians agree, they may be able to stay on endocrine therapy for up to three years. Average overhead booked to program in fy2024 = 7.2%